SynthesisInternational journal of obesity (2005)2008
Metformin and body weight.
Synthesis in International journal of obesity (2005), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05032001 (ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.), which is not on this map. Cited by 68 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.
Who cites it
68 citing papers in PubMed, 5 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- The Association between Metformin Therapy and Lactic Acidosis.Drug safety · 2019Pooled it
- The effects of metformin on simple obesity: a meta-analysis.Endocrine · 2018Pooled it
- Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis.PloS one · 2018Pooled it
- The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.BMC infectious diseases · 2010Pooled it
- Metformin for obesity in children and adolescents: a systematic review.Diabetes care · 2009Pooled it
- Metformin increases glycolysis and the stress-induced cytokine GDF15 but not FGF21 in humans.Frontiers in endocrinology · 2026Trial
- A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.European heart journal · 2019 · on this mapTrial
- Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.Clinical drug investigation · 2017Trial
- Trial
- Trial
- Metformin abuse and weight loss: A case report.World journal of clinical cases · 2025Article
- Impact of immediate-release versus extended-release metformin on lipid profile and body measurements in Saudi patients with type 2 diabetes: a prospective cohort study.The Pan African medical journal · 2025Article
- A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications.Current molecular medicine · 2025Review
- The Art and Science of Antidiabetic Medications and Obesity Management.Mini reviews in medicinal chemistry · 2025Review
- Article
- Proteomic Profiling Identifies Distinct Regulation of Proteins in Obese Diabetic Patients Treated with Metformin.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Management of hyperglycaemia in people with obesity.Clinical medicine (London, England) · 2023Article
- Role of obesity related inflammation in pathogenesis of peripheral artery disease in patients of type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2023Review
- Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice.Nutrients · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors. However, many antidiabetic treatments increase body weight. The oral antidiabetic agent, metformin, has been evaluated in hundreds of clinical studies in diverse patient populations during approximately five decades of clinical use. This review summarizes the effects of metformin on body weight, with special reference to studies of longer duration (>/=6 months) as both diabetes and obesity are long-term conditions. Approximately half of studies in drug-naive type 2 diabetic patients demonstrated significant weight loss with metformin compared with baseline or comparator drugs, although pooled analyses have suggested no significant effect versus placebo. Similarly, metformin has been shown to induce weight loss in obese nondiabetic populations, although studies of long duration in this population are scarce. Metformin does appear to mitigate the adverse effects of insulin on body weight. The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.